Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma

BMC Urology

Volumn 13, Issue , 2013, Pages

  Venugopal, Balaji ^a   Ansari, Jawaher ^a   Aitchison, Michael ^a,b   Tho, Lye Mun ^a,b   Campbell, Roderick ^c   Jones, Rob J ^a,b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

Author keywords

Chromophobe renal cell carcinoma; Renal cell cancer; Temsirolimus

Indexed keywords

ANTIBIOTIC AGENT; STEROID; SUNITINIB; TEMSIROLIMUS;

ACUTE DISEASE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BONE ATROPHY; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY MASS; KIDNEY METASTASIS; LAPAROSCOPIC SURGERY; LYMPHADENOPATHY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECOMMENDED DRUG DOSE; SPINAL CORD COMPRESSION; STEROID THERAPY; TEMSIROLIMUS INDUCED PNEUMONITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877904949     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-26     Document Type: Article

References (16)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 10.3322/caac.20107 21296855
2. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Gore ME, Larkin JMG, Br J Cancer 2011 104 3 399 406 10.1038/sj.bjc.6606084 21285971
3. The Heidelberg classification of renal cell tumours. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, J Pathol 1997 183 2 131 133 10.1002/(SICI)1096-9896(199710)183: 2<131::AID-PATH931>3.0.CO;2-G 9390023
4. Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. Tickoo SK, Amin MB, Zarbo RJ, Am J Surg Pathol 1998 22 4 419 424 10.1097/00000478-199804000-00005 9537468 (Pubitemid 28164547)
5. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. Patard J-J, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, J Clin Oncol 2005 23 12 2763 2771 15837991 (Pubitemid 46179466)
6. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, N Engl J Med 2007 356 22 2271 2281 10.1056/NEJMoa066838 17538086 (Pubitemid 46849157)
7. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, N Engl J Med 2007 356 2 115 124 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
8. Treatment outcome and survival associated with metastatic renal cell carcinoma of Non-clear-cell histology. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V, J Clin Oncol 2002 20 9 2376 2381 10.1200/JCO.2002.11.123 11981011 (Pubitemid 34441667)
9. Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma. Patel PH, Chadalavada RSV, Chaganti RSK, Motzer RJ, Clin Cancer Res 2006 12 24 7215 7220 10.1158/1078-0432.CCR-06-2254 17189392 (Pubitemid 46095391)
10. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Dutcher J, de Souza P, McDermott D, Figlin R, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G, Medical Oncology 2009 26 2 202 209 10.1007/s12032-009-9177- 0 19229667
11. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B, J Clin Oncol 2008 26 1 127 131 10.1200/JCO.2007.13.3223 18165647
12. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. Larkin JMG, Fisher RA, Pickering LM, Sohaib SA, Ghosn M, Christmas T, Cordiner RLM, Gore ME, J Clin Oncol 2011 29 9 241 e242 10.1200/JCO.2010.33.4375 21245426
13. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Paule B, Brion N, Anticancer Res 2011 31 1 331 333 21273619
14. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Zardavas D, Meisel A, Samaras P, Knuth A, Renner C, Pestalozzi BC, Stenner-Liewen F, Case Reports Oncol 2011 4 1 16 18 10.1159/000323804
15. Targeting the mTOR pathway in chromophobe kidney cancer. Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R, J Cancer 2012 3 152 157 22481981
16. Armstrong A, Phase II Study of Afinitor vs. Sutent in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN) 2012 Current clinical trial. http://clinicaltrials.gov/show/NCT01108445